174 related articles for article (PubMed ID: 36227698)
1. Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism.
Gutierrez WR; Scherer A; Rytlewski JD; Laverty EA; Sheehan AP; McGivney GR; Brockman QR; Knepper-Adrian V; Roughton GA; Quelle DE; Gordon DJ; Monga V; Dodd RD
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36227698
[TBL] [Abstract][Full Text] [Related]
2. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
3. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
5. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
6. Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy.
Alexandraki A; Strati K
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430521
[TBL] [Abstract][Full Text] [Related]
7. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
[TBL] [Abstract][Full Text] [Related]
8. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
9. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
10. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
11. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
12. Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation.
Wang L; Guo X; Guo X; Zhang X; Ren J
Eur J Pharmacol; 2019 Nov; 863():172676. PubMed ID: 31542488
[TBL] [Abstract][Full Text] [Related]
13. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells.
Lin L; Liu X; Yu H; Deng H; Peng K; Chen J; Zhang C; Jiang T; Liu X
Front Pharmacol; 2023; 14():1134895. PubMed ID: 36937854
[No Abstract] [Full Text] [Related]
15. Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts.
Wang B; Li H; Yang R; Zhou S; Zou S
Oncol Lett; 2014 Nov; 8(5):1919-1924. PubMed ID: 25295073
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
Abou Najem S; Khawaja G; Hodroj MH; Rizk S
Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
[TBL] [Abstract][Full Text] [Related]
18. Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.
Li L; Liu W; Sun Q; Zhu H; Hong M; Qian S
Oxid Med Cell Longev; 2021; 2021():8877460. PubMed ID: 33532040
[TBL] [Abstract][Full Text] [Related]
19. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.
Zhou J; Yao Y; Shen Q; Li G; Hu L; Zhang X
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1371-1380. PubMed ID: 28321548
[TBL] [Abstract][Full Text] [Related]
20. Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
Lillo Osuna MA; Garcia-Lopez J; El Ayachi I; Fatima I; Khalid AB; Kumpati J; Slayden AV; Seagroves TN; Miranda-Carboni GA; Krum SA
Cancer Res; 2019 Mar; 79(6):1054-1068. PubMed ID: 30593524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
